We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Biotech Earnings Battle: Gilead (GILD) vs. Amgen (AMGN)
Read MoreHide Full Article
In this video, we take a look at two of the biggest and most important companies in the biotech space. Both are reporting earnings this week, and given the volatile nature of the sector lately, it will definitely be in investors’ best interest to see how two of the top dogs in this market fare in their quarterly reports.
After all, the space is likely to face some political risks with the upcoming election, while there are definitely valuation concerns. And given a top 30% industry rank, there are going to be plenty of stocks to buy in this space, but also a few to avoid too.
First, let’s take a quick look at Gilead Sciences (GILD - Free Report) , a California-based giant with a market cap over $100 billion. The stock currently has a Zacks Rank #2 (buy), while it has an ‘A’ Score for its VGM, so fundamentals are pretty impressive. However, it did just miss estimates to break its impressive streak, while growth rates aren’t that inspiring, making this a real mixed bag heading into earnings.
Next up we have Amgen (AMGN - Free Report) , another large cap company which reports this week. The company is riding an impressive streak at earnings season which includes beats/meets in every quarter since early 2013. It is seeing solid growth projections, but it has been stuck in a narrow range in recent months. Add in a Zacks Rank #3 (hold) and a ‘B’ VGM score, and some of its fundamentals aren’t quite as good as GILD heading into the report.
The biotech industry is promising overall and it currently has an Industry Rank in the top 30%, so either could be intriguing, though we discuss the better pick in the video. Make sure to watch for the selection, as well as more insights on both of these companies, including a more thorough discussion of their charts. And if you’d like more information on how to trade earnings reports, make sure to check out our podcast below:
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Biotech Earnings Battle: Gilead (GILD) vs. Amgen (AMGN)
In this video, we take a look at two of the biggest and most important companies in the biotech space. Both are reporting earnings this week, and given the volatile nature of the sector lately, it will definitely be in investors’ best interest to see how two of the top dogs in this market fare in their quarterly reports.
After all, the space is likely to face some political risks with the upcoming election, while there are definitely valuation concerns. And given a top 30% industry rank, there are going to be plenty of stocks to buy in this space, but also a few to avoid too.
First, let’s take a quick look at Gilead Sciences (GILD - Free Report) , a California-based giant with a market cap over $100 billion. The stock currently has a Zacks Rank #2 (buy), while it has an ‘A’ Score for its VGM, so fundamentals are pretty impressive. However, it did just miss estimates to break its impressive streak, while growth rates aren’t that inspiring, making this a real mixed bag heading into earnings.
GILEAD SCIENCES Price, Consensus and EPS Surprise
GILEAD SCIENCES Price, Consensus and EPS Surprise | GILEAD SCIENCES Quote
Next up we have Amgen (AMGN - Free Report) , another large cap company which reports this week. The company is riding an impressive streak at earnings season which includes beats/meets in every quarter since early 2013. It is seeing solid growth projections, but it has been stuck in a narrow range in recent months. Add in a Zacks Rank #3 (hold) and a ‘B’ VGM score, and some of its fundamentals aren’t quite as good as GILD heading into the report.
AMGEN INC Price, Consensus and EPS Surprise
AMGEN INC Price, Consensus and EPS Surprise | AMGEN INC Quote
The biotech industry is promising overall and it currently has an Industry Rank in the top 30%, so either could be intriguing, though we discuss the better pick in the video. Make sure to watch for the selection, as well as more insights on both of these companies, including a more thorough discussion of their charts. And if you’d like more information on how to trade earnings reports, make sure to check out our podcast below: